

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

Equality impact assessment – Guidance development

Ambulight PDT for the treatment of non-melanoma skin cancer

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

Ambulight PDT is intended for use in patients with small non-melanoma skin cancer and could be used in an ambulatory setting. It is highlighted in the consultation document that patients who might otherwise have difficulty accessing PDT such as those with impaired mobility, could be treated with Ambulight PDT.

- | |
|---|
| 2. Have any other potential equality issues been highlighted in the manufacturer's submission, or patient organisation questionnaires, and, if so, how has the Committee addressed these? |
|---|

No additional equality issues were highlighted in the manufacturer's submission or in patient organisation questionnaires.
--

- | |
|---|
| 3. Have any other potential equality issues been identified by the Committee and, if so, how has the Committee addressed these? |
|---|

No additional equality issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The draft recommendations will not lead to differential access to Ambulight PDT. These draft recommendations are not supportive of the device being recommended for routine use in the NHS.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

None.

6. Have the Committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

The Committee's considerations of equality issues are described in section 3.13 of the consultation document.

Approved by Associate Director (name): Mark Campbell

Date: 1/08/11

Medical technologies guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during the consultation.

2. If the recommendations have changed after consultation, are there

any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?
If so, what are the barriers to access for the specific group?

The recommendations did change after consultation but the final recommendations did not identify specific subgroups and will not lead to differential access to Ambulight PDT, since the final recommendations are not supportive of the device being recommended for routine use in the NHS.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

None.

4. Have the Committee's considerations of equality issues been described in the medical technologies guidance document, and, if so, where?

The Committee's considerations of equality issues are described in section 3.8 of the guidance.

Approved by Programme Director (name): Mirella Marlow

Date: 1/8/11